{"id":3334,"date":"2025-03-24T14:15:34","date_gmt":"2025-03-24T11:15:34","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=3334"},"modified":"2025-03-24T14:26:43","modified_gmt":"2025-03-24T11:26:43","slug":"entrada-therapeutics-receives-uk-authorization-to-begin-elevate-45-201-a-phase-1-2-multiple-ascending-dose-clinical-study-of-entr-601-45-in-duchenne-muscular-dystrophy-patients-amenable-to-exon-45-sk","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/entrada-therapeutics-receives-uk-authorization-to-begin-elevate-45-201-a-phase-1-2-multiple-ascending-dose-clinical-study-of-entr-601-45-in-duchenne-muscular-dystrophy-patients-amenable-to-exon-45-sk\/","title":{"rendered":"Entrada Therapeutics, Birle\u015fik Krall\u0131k&#039;ta ELEVATE-45-201&#039;i Ba\u015flatmak \u0130\u00e7in Yetki Ald\u0131"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Entrada Therapeutics, Birle\u015fik Krall\u0131k \u0130la\u00e7 ve Sa\u011fl\u0131k \u00dcr\u00fcnleri D\u00fczenleme Kurumu (MHRA) ve Ara\u015ft\u0131rma Etik Komitesi&#039;nden ELEVATE-45-201&#039;i ba\u015flatmak i\u00e7in yetki ald\u0131\u011f\u0131n\u0131 duyurdu. ELEVATE-45-201, ekzon 45 atlamaya uygun DMD geninde do\u011frulanm\u0131\u015f mutasyonu olan hastalarda Duchenne kas distrofisi (DMD) tedavisi i\u00e7in Entrada&#039;nin ara\u015ft\u0131rma ama\u00e7l\u0131 t\u0131bbi \u00fcr\u00fcn\u00fc ENTR-601-45&#039;in potansiyel tedavisini de\u011ferlendirmek \u00fczere bir Faz 1\/2 \u00e7oklu artan doz (MAD) klinik \u00e7al\u0131\u015fmas\u0131d\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Daha fazla bilgi edin: <a href=\"https:\/\/dmdwarrior.com\/tr\/what-is-exon-skipping-and-how-does-it-work\/\" target=\"_blank\" data-type=\"post\" data-id=\"1445\" rel=\"noreferrer noopener\">Ekzon Atlama Nedir?<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Entrada Therapeutics, announced it has received authorization from the United Kingdom\u2019s Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee to initiate ELEVATE-45-201. ELEVATE-45-201 is a Phase 1\/2 multiple ascending dose (MAD) clinical study to evaluate Entrada\u2019s investigational medicinal product ENTR-601-45 for the potential treatment of Duchenne muscular dystrophy (DMD) in patients with [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3335,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[320,321,234,317,318,319,48,322],"class_list":["post-3334","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-elevate-45-201","tag-entr-601-45","tag-entrada-therapeutics","tag-exon-45","tag-exon-45-skipping","tag-exon-45-skipping-therapy","tag-uk","tag-united-kingdom"],"subtitle":"\u0130ngiltere \u0130la\u00e7 ve Sa\u011fl\u0131k \u00dcr\u00fcnleri D\u00fczenleme Kurumu (MHRA) ve Ara\u015ft\u0131rma Etik Komitesi, Entrada Therapeutics'ye ELEVATE-45-201 \u00e7al\u0131\u015fmas\u0131n\u0131 ba\u015flatma izni verdi.","_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/3334","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=3334"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/3334\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/3335"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=3334"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=3334"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=3334"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}